

Supplementary Online Content

Ma TM, Romero T, Nickols NG, et al. Comparison of response to definitive radiotherapy for localized prostate cancer in Black and White men: a meta-analysis. *JAMA Netw Open*. 2021;4(12):e2139769.
doi:10.1001/jamanetworkopen.2021.39769

eFigure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses Flowchart

eFigure 2. Percentage of All-Cause Mortality Events Attributable to Prostate Cancer–Specific Mortality

eFigure 3. Percentage of All-Cause Mortality Events Attributable to Prostate Cancer–Specific Mortality in Specific Subgroups

eFigure 4. Forest Plots of Association Between Race and Other Cause Mortality and Death or Distant Metastasis


eTable 1. Summary of Trials Included in Network Meta-analysis

eTable 2. Treatment Strategies as Defined by Individual Trial Treatment Arms

eTable 3. Crude Event Rates Per Trial, Stratified by Race and Treatment Strategy


This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flowchart




eFigure 2. Percentage of All-Cause Mortality Events Attributable to Prostate


Cancer-Specific Mortality. A lower percentage of mortality events were due to PCSM rather than OCM overall (50/773 [6.5%] vs. 368/3617 [10.2%]), and among men aged <65 (17/225 [7.6%] vs. 93/624 [14.9%]) and ≥65 (33/548 [6.0%] vs. 275/2993 [9.2%]) as well as men with high-risk disease (24/374 [6.4%] vs. 188/1480 [12.7%]).



eFigure 3. Percentage of All-Cause Mortality Events Attributable to Prostate Cancer-Specific Mortality in Specific Subgroups



eFigure 4. Forest Plots of Association Between Race and Other Cause Mortality and Death or Distant Metastasis



eTable 1. Summary of Trials Included in Network Meta-Analysis

Trial	Arms	Inclusion*	Primary Endpoint	RT Dose
RTOG 9202 (1992-1995)	RT + 4 mos ADT RT + 28 mos ADT	cT2-4N0-X, PSA<150	Disease-free survival	65-70 Gy to prostate 44-46 Gy to pelvis
RTOG 9408 (1994-2001)	RT RT + 4 mos ADT	cT1b-T2b PSA≤20	Overall survival	66.6 Gy to prostate 46.8 Gy to pelvis
RTOG 9413 (1995-1999)	Prostate-only RT + adjuvant ADT WPRT + adjuvant ADT Prostate-only RT + neoadjuvant/concurrent ADT WPRT + neoadjuvant/concurrent ADT	PSA≤100 Ineligible for RTOG 9408	Progression free survival	70.2 Gy to prostate 50.4 Gy to pelvis
RTOG 9902 (2000-2004)	RT + 24 mos ADT RT + 24mos ADT+TEEx4	PSA 20-100, GS≥7, any T OR ≥cT2, GS 8-10, PSA≤100	Disease-free survival	70.2 Gy to prostate 46.8 Gy to pelvis
RTOG 9910 (2000-2004)	RT + 4 mos ADT RT + 9 mos ADT	cT1b-4, PSA>10 but ≤100, and GS 2-6 OR cT1b-4, PSA<20, GS 7 OR cT1b-c, PSA<20, GS 8-10	Disease-specific survival	70.2 Gy to prostate 46.8 Gy to pelvis (if no staging surgery)
RTOG 0126 (2002-2008)	Moderate dose RT High dose RT	cT1b-T2b, GS 2-6, PSA≥10 but <20 OR cT1b-T2b, GS 7, PSA<15	Overall survival	70.2 Gy to prostate 79.2 Gy to prostate
RTOG 0415 (2006-2009)	Conventionally-fractionated RT Hypofractionated RT	cT1b-T2c, GS 2-6, PSA<10	Disease-free survival	73.8 Gy to prostate 70 Gy (in 28 fractions) to prostate

*Patients with cN+ or pN+ disease were not included in our analysis.

ADT, androgen deprivation therapy; CT, computed tomography; GS, Gleason score; PSA, prostate-specific antigen; LHRH, luteinizing hormone releasing hormone; MRI, magnetic resonance imaging; Gy, gray; RT, radiation therapy; TEE, paclitaxel, estramustine, and oral etoposide; WPRT, whole pelvis radiation therapy

eTable 2. Treatment Strategies As Defined by Individual Trial Treatment Arms

Treatment Strategy	Trial Arms
RT Alone	RTOG 9408 RT alone
	RTOG 0126 RT alone (control arm)
	RTOG 0415 Conventionally fractionated RT alone
	RTOG 0415 Moderately hypofractionated RT alone
RT+STADT	RTOG 9202 RT + 4 months ADT
	RTOG 9408 RT + 4 months ADT
	RTOG 9413 Prostate-only RT + adjuvant 4 months ADT
	RTOG 9413 Whole pelvis RT + adjuvant 4 months ADT
	RTOG 9413 Prostate-only RT + neoadjuvant/concurrent 4 months ADT
	RTOG 9413 Whole pelvis RT + neoadjuvant/concurrent 4 months ADT
	RTOG 9910 RT + 4 months ADT RTOG 9910 RT + 9 months ADT
RT+LTADT	RTOG 9202 RT + 28 months ADT
	RTOG 9902 RT + 24 months ADT
	RTOG 9902 RT + 24 months ADT + TEE _{x4}
High Dose RT	RTOG 0126 high dose RT (experimental arm)

ADT, androgen deprivation therapy; LTADT, long-term ADT; RT, radiation therapy; STADT, short-term ADT; TEE, paclitaxel, estramustine, and oral etoposide

eTable 3. Crude Event Rates Per Trial, Stratified by Race and Treatment Strategy

Trial	Treatment	Black					White				
		Total	Number of Events				Total	Number of Events			
			BCR	DM	PCSM	ACM		BCR	DM	PCSM	ACM
RTOG 9202	RT+STADT	83	43	19	13	62	617	375	159	115	501
RTOG 9202	RT+LTADT	103	47	13	8	81	611	269	106	83	482
RTOG 9408	RT Alone	197	84	17	17	135	754	375	80	95	521
RTOG 9408	RT+STADT	197	52	11	10	113	743	280	53	51	516
RTOG 9413	RT+STADT	322	150	49	0	220	881	443	193	0	667
RTOG 9902	RT+LTADT	102	51	6	0	33	265	149	43	0	105
RTOG 9910	RT+STADT	246	57	6	0	70	1190	308	71	0	371
RTOG 0126	RT Alone	84	26	3	0	19	643	300	45	17	192
RTOG 0126	High Dose	104	30	6	2	27	609	186	24	4	177
RTOG 0415	RT Alone	192	16	0	0	13	871	69	0	3	85
Total		1630	556	130	50	773	7184	2754	774	368	3617
Crude Event Rate			34.1%	8%	3.1%	47.4%		38.3%	10.8%	5.1%	50.3%

ACM, all-cause mortality; BCR, biochemical recurrence; DM, distant metastasis; LTADT, long-term androgen deprivation therapy; PCSM, prostate cancer-specific mortality; RT, radiotherapy; STADT, short-term androgen deprivation therapy

*Based on trial outcomes, patients enrolled on RTOG 9413, 9902, and 9910 were considered to have received the same treatment in all arms.